✦ LIBER ✦

PDB33 The Associated Costs of Treating Type 2 Diabetes Patients to a Clinically Relevant Composite Endpoint With Liraglutide Versus Exenatide

✍ Scribed by J. Langer; J.R. Bouchard

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Real World Outcomes in Type 2 Diabetes:

✍ Dekoven, M.; Lee, W.C.; Bouchard, J.R.; Massoudi, M.; Langer, J. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Cost Analysis Of Treatment Success To Ac

✍ Shi, L.W.; HAN, S.; Ploug, U.J.; LIU, F. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 89 KB

PDB14 Assessing Treatment Success of Dia

✍ J. Langer; J.R. Bouchard; U.J. Ploug 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PDB18 COST OFFSETS ASSOCIATED WITH USE O

✍ MD Pawaskar; J Anderson; AJ Zagar 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Evaluating the Long-Term Cost-Effectiven

✍ William J. Valentine; Andrew J. Palmer; Morten Lammert; Jakob Langer; Michael Br 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 505 KB

PDB36 Reduced Rates of Hypoglycemia Lead

✍ D.L. Becker; S.W. Thayer; B. Zhang; M. Skornicki; J.P. Graham; K.F. Bell 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB